Xtandi 40 MG capsule 120S
Ended Awarded Last action
- Contract number
- SPE2DR26FHGU8
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $12,766
Award facts
- Contract value 100% obligated
- $12,766.02 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a delivery order valued at $12,766.02 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (120-count units). This firm fixed-price delivery order, awarded on December 17, 2025, with an ultimate completion date of December 18, 2025, was issued without a set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The award falls under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which was established on November 13, 2025, with a $499.999 billion ceiling value and completion date of December 31, 2036.
DMS Pharmaceutical Group serves as a critical pharmaceutical supplier within the Department of Defense's global healthcare operations through the PPV-G GEN V program, a $30.3 billion acquisition strategy designed to streamline pharmaceutical supply chains across military medical facilities worldwide. The company's established performance on numerous delivery orders for diverse pharmaceutical products—including oncology treatments, biologics, vaccines, and specialty pharmaceuticals—demonstrates its capability to fulfill the specialized medical supply requirements of federal military healthcare systems. As a registered federal contractor since 2001, DMS Pharmaceutical Group maintains consistent contract performance and leverages its small business status to compete effectively in government pharmaceutical procurement.
Quick answers
Who was awarded contract SPE2DR26FHGU8?
SPE2DR26FHGU8 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 17, 2025.
How much is contract SPE2DR26FHGU8 worth?
The government has obligated $12,766 on SPE2DR26FHGU8.
Is contract SPE2DR26FHGU8 an order under another contract?
Yes. SPE2DR26FHGU8 is a delivery order under SPE2DR25D9244, an indefinite delivery contract.
Was contract SPE2DR26FHGU8 competed?
The extent of competition for SPE2DR26FHGU8 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award